CD79A and COVID-19: In order to understand the behavior of the IBMP Spike IgA/IgM/IgG ELISA and other commercial tests during COVID-19 seroconversion, we analyzed the arithmetic mean of the reactivity index in relation to days post symptom onset (Figure 7).